Oral oxytocin for abdominal pain

Descripción del proyecto

Un nuevo método para el tratamiento del dolor abdominal crónico

Millones de personas en el mundo padecen dolor abdominal crónico, una afección a menudo relacionada con el síndrome del colon irritable y las enfermedades inflamatorias intestinales. Con más del 10 % de la población mundial afectada, su tratamiento cuesta a Europa unos 115 000 millones EUR cada año. Por ello, se necesita una solución segura y específica. En este contexto, el proyecto GUTOCINS, financiado por el Consejo Europeo de Investigación, aborda este reto desarrollando analgésicos peptídicos estables en el intestino que alivian el dolor directamente en su origen. Este método garantiza una gran eficacia y, al mismo tiempo, reduce los efectos secundarios sistémicos. Mediante la optimización de compuestos patentados para convertirlos en candidatos a fármacos orales y la generación de datos preclínicos, en GUTOCINS se pretende favorecer la traslación clínica de este nuevo método, el cual también podría ayudar a reducir la carga social de estas enfermedades crónicas.

Objetivo

Chronic abdominal pain is a widespread debilitating condition commonly associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). IBS and IBD affect more than 10% of the global population, leaving a severe and steadily growing socio-economic burden on society (€115 billion/year in Europe in direct and indirect health care costs). Adequate pain management for these conditions is imperative but remains challenging since classical analgesics are poorly effective, associated with adverse effects, and can even exacerbate disease progression.

In this project, we will advance a new class of gut-stable peptide analgesics to target abdominal pain at its origin in the gut. This represents a highly innovative treatment strategy with a large safety window due to its gut-specific action and negligible risk of systemic off-target effects. It also addresses a long-standing problem in the peptide therapeutics industry, namely the lack of oral peptide drugs. The objective of this project is to optimise our patented lead compounds towards oral drug candidates and generate robust and supporting preclinical data for clinical translation. The proof-of-concept data will then be used to engage with industry partners and other supporters to advance these drug candidates into the clinic for the treatment of chronic abdominal pain. Our gut-specific treatment approach along with this new class of analgesics could induce a highly desired paradigm shift in how to treat chronic abdominal pain and gastrointestinal disorders, an area with unprecedented unmet medical need. This could benefit millions of people worldwide, improve their quality of life, and help reduce the substantial socio-economic burden that chronic abdominal pain has on society.